BACKGROUND: In locally advanced rectal cancer, therapeutic success of preoperative chemoradiotherapy (CRT) ranges from resistance to complete regression. For those patients that respond well to CRT, local resection (LR) procedures are currently under investigation to minimize surgical morbidity and to improve functional outcome. To maintain the oncologic benefit appropriate staging procedures are essential. However, current clinical assessment and imaging techniques need further improvement. METHODS: Five miRNAs associated with rectal cancer (miR-17, miR-18b, miR-20a, miR-31, and miR-193-3p) were analyzed in the plasma of rectal cancer patients (n = 42) using qPCR. Expression levels were assessed before, during and after CRT and analyzed in regard to patients' lymph node status obtained after total mesorectal excision and intensive histopathological work-up. RESULTS: Four of the five miRNAs revealed reliable results in the plasma. miR-31 was excluded due to its low expression. MicroRNA-17, 18b, 20a, and 193-3p showed altering expression levels at different time points. Only 43% (miR-17), 43% (miR-18b), 53% (miR-20a), and 60% (miR-193-3p) showed a continuous in- or decrease of miRNA expression. The reduced expression of miR-18b and miR-20a during CRT was found to be significantly associated with postoperative lymph node negativity (p < 0.05). CONCLUSION: MicroRNA expression in patient plasma changes during preoperative CRT. The alteration is not continuous and the meaning requires additional analysis on a larger patient cohort. The co-occurrence of reduced miR-18b and miR-20a expression with lymph node negativity after preoperative CRT could help to stratify the surgical procedure with respect to total mesorectal excision and LR if validated prospectively.
BACKGROUND: In locally advanced rectal cancer, therapeutic success of preoperative chemoradiotherapy (CRT) ranges from resistance to complete regression. For those patients that respond well to CRT, local resection (LR) procedures are currently under investigation to minimize surgical morbidity and to improve functional outcome. To maintain the oncologic benefit appropriate staging procedures are essential. However, current clinical assessment and imaging techniques need further improvement. METHODS: Five miRNAs associated with rectal cancer (miR-17, miR-18b, miR-20a, miR-31, and miR-193-3p) were analyzed in the plasma of rectal cancerpatients (n = 42) using qPCR. Expression levels were assessed before, during and after CRT and analyzed in regard to patients' lymph node status obtained after total mesorectal excision and intensive histopathological work-up. RESULTS: Four of the five miRNAs revealed reliable results in the plasma. miR-31 was excluded due to its low expression. MicroRNA-17, 18b, 20a, and 193-3p showed altering expression levels at different time points. Only 43% (miR-17), 43% (miR-18b), 53% (miR-20a), and 60% (miR-193-3p) showed a continuous in- or decrease of miRNA expression. The reduced expression of miR-18b and miR-20a during CRT was found to be significantly associated with postoperative lymph node negativity (p < 0.05). CONCLUSION: MicroRNA expression in patient plasma changes during preoperative CRT. The alteration is not continuous and the meaning requires additional analysis on a larger patient cohort. The co-occurrence of reduced miR-18b and miR-20a expression with lymph node negativity after preoperative CRT could help to stratify the surgical procedure with respect to total mesorectal excision and LR if validated prospectively.
Authors: Marije P van der Paardt; Marjolein B Zagers; Regina G H Beets-Tan; Jaap Stoker; Shandra Bipat Journal: Radiology Date: 2013-06-25 Impact factor: 11.105
Authors: Guus M J Bökkerink; Eelco J R de Graaf; Cornelis J A Punt; Iris D Nagtegaal; Heidi Rütten; Joost J M E Nuyttens; Esther van Meerten; Pascal G Doornebosch; Pieter J Tanis; Eric J Derksen; Roy S Dwarkasing; Corrie A M Marijnen; Annemieke Cats; Rob A E M Tollenaar; Ignace H J T de Hingh; Harm J T Rutten; George P van der Schelling; Albert J Ten Tije; Jeroen W A Leijtens; Guido Lammering; Geerard L Beets; Theo J Aufenacker; Apollo Pronk; Eric R Manusama; Christiaan Hoff; Andreas J A Bremers; Cornelelis Verhoef; Johannes H W de Wilt Journal: BMC Surg Date: 2011-12-15 Impact factor: 2.102
Authors: Lucy Pigati; Sree C S Yaddanapudi; Ravi Iyengar; Dong-Ja Kim; Steven A Hearn; David Danforth; Michelle L Hastings; Dominik M Duelli Journal: PLoS One Date: 2010-10-20 Impact factor: 3.240
Authors: Jochen Gaedcke; Marian Grade; Jordi Camps; Rolf Søkilde; Bogumil Kaczkowski; Aaron J Schetter; Michael J Difilippantonio; Curtis C Harris; B Michael Ghadimi; Søren Møller; Tim Beissbarth; Thomas Ried; Thomas Litman Journal: Clin Cancer Res Date: 2012-07-31 Impact factor: 12.531
Authors: Carina Roth; Brigitte Rack; Volkmar Müller; Wolfgang Janni; Klaus Pantel; Heidi Schwarzenbach Journal: Breast Cancer Res Date: 2010-11-03 Impact factor: 6.466
Authors: Daniela Musio; Francesca De Felice; Anna Lisa Magnante; Maria Ciolina; Carlo Nicola De Cecco; Marco Rengo; Adriano Redler; Andrea Laghi; Nicola Raffetto; Vincenzo Tombolini Journal: Biomed Res Int Date: 2013-07-10 Impact factor: 3.411
Authors: Azadeh Azizian; Ingo Epping; Frank Kramer; Peter Jo; Markus Bernhardt; Julia Kitz; Gabriela Salinas; Hendrik A Wolff; Marian Grade; Tim Beißbarth; B Michael Ghadimi; Jochen Gaedcke Journal: Int J Mol Sci Date: 2016-04-15 Impact factor: 5.923
Authors: Maarten Neerincx; Dennis Poel; Daoud L S Sie; Nicole C T van Grieken; Ram C Shankaraiah; Floor S W van der Wolf-de Lijster; Jan-Hein T M van Waesberghe; Jan-Dirk Burggraaf; Paul P Eijk; Cornelis Verhoef; Bauke Ylstra; Gerrit A Meijer; Mark A van de Wiel; Tineke E Buffart; Henk M W Verheul Journal: PLoS One Date: 2018-08-03 Impact factor: 3.240